Form 4: Imunon Inc. Chief Scientific Officer Acquires Stock Options
SEC Form 4 Filing
Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., reports acquisition of stock options.
Summary
- Khursheed Anwer, the Chief Scientific Officer of Imunon, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction on March 15, 2024, where Anwer acquired 25,000 stock options with an exercise price of $0.86.
- The options vest in installments: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary.
- The options expire on March 15, 2034.
- Following the reported transaction, Anwer directly owns 110,688 shares of Imunon, Inc. common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports an insider transaction, which can be interpreted as a sign of confidence but doesn't inherently indicate positive or negative performance.
Positives
- The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This is a standard SEC filing related to insider transactions. It's common for executives to receive stock options as part of their compensation packages.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of stock option grant and transaction. |
| 03/15/2034 | Expiration date of the stock options. |
| 03/18/2024 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Imunon, Stock Options, Beneficial Ownership, Anwer, IMNN, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.